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Abstract Doxorubicin (DOX) is a potent antitumor
agent for diVerent types of cancer, but the cumulative,
dose-related cardiotoxicity limits its clinical use. The
incidence of abnormal cardiac function after treatment
with DOX appears to increase with time. Therefore,
late cardiotoxicity is—especially in young surviving
patients—a major concern. The aim of this study was to
evaluate in mice whether the semisynthetic Xavonoid
7-monohydroxyethylrutoside (monoHER) also protected
against DOX-induced cardiotoxicity after a long
period of follow-up. Four groups of 6 Balb/c mice
were treated weekly during 6 weeks with saline, DOX
alone (4 mg/kg i.v.), DOX preceded by monoHER
(500 mg/kg i.p.), or DOX preceded by monoHER fol-
lowed by long-term weekly monoHER injections dur-
ing the observation period of 6 months. Half of the
mice treated with DOX only developed DOX-
induced heart failure and died within 6 months of
observation. Two mice co-treated with monoHER
showed weight loss and shortness of breath, whereas
one mouse was found dead in its cage known with
weight loss. The group receiving DOX plus long-term
repeated doses of monoHER started to lose weight.
Five out of six mice in this group developed shortness
of breath and died before the end of the study with
symptoms of cardiac failure induced by DOX. Statis-
tical comparison of the histological heart damage
between the diVerent experimental groups was not
possible, because the animals died at diVerent time-
points in the observation period and DOX-induced
cardiotoxicity progressed with time. Nevertheless, it
was clear that the initial cardioprotective eVect of
monoHER was not prolonged during the half-year
observation period. It was even suggested that addi-
tion of repeated doses of monoHER tended to aggra-
vate DOX-induced cardiotoxicity. It cannot be
excluded that the dose and frequency of monoHER
administration is crucial in obtaining an optimal anti-
oxidant activity without a pro-oxidant activity of
monoHER.
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The clinical eYcacy of the chemotherapeutic agent
doxorubicin (DOX) is severely limited by its dose-lim-
iting cardiotoxicity in patients with cancer [9, 13, 16,
20]. The most common hypothesis for the mechanism
by which DOX induces cardiac damage includes the
formation of free radicals [8, 26]. Heart tissue is partic-
ularly susceptible to free radicals because the concen-
tration of enzymes protecting against oxidative damage
is lower than that in other tissues [9, 10].
Several clinical studies showed that the incidence of
abnormal cardiac function after treatment with DOX
appears to increase with time [11, 14, 18]. In survivors
of childhood cancer, the incidence of cardiac abnormal-
ities also increased with the length of follow-up [11, 14].
More than 65% of children with cancer achieve long-
term survival and because many of these survivors will
have received DOX or another anthracycline, late
anthracycline cardiotoxicity is a major concern [5, 17].
The importance to minimize or completely prevent
this severe side eVect of DOX treatment is clear. In
the past we have identiWed the cardioprotective prop-
erties of 7-monohydroxyethylrutoside (monoHER)
against DOX-induced cardiotoxicity in mice [23, 24]
without inXuencing the antitumor eVect of DOX. Its
cardioprotection is believed to result from protection
against DOX-induced free radicals through radical
scavenging and iron chelating properties of mono-
HER [6, 22]. The cardioprotective eVect of mono-
HER was dose-dependent and a dose of 500 mg/kg
monoHE, 1 h before DOX completely protected
against DOX-induced cardiotoxicity [23]. In all previ-
ous studies the protective properties of monoHER
were evaluated during a 6-week treatment period and
2 weeks thereafter. Because the incidence of ventricu-
lar dysfunction continues to increase with time it is
important to know whether the cardioprotective
eVect of monoHER is still present after a long period
of follow-up.
Therefore, the aim of the present study was to evaluate
the cardioprotective eVect of monoHER in DOX-
treated mice during a period of 6 months. The morpho-
logical changes in the cardiac tissue were evaluated by
microscopic examination.
Materials and methods
Chemicals
7-Monohydroxyethylrutoside (monoHER) was kindly
provided by Novartis Consumer Health (Nyon,
Switzerland). The drug was formulated and dissolved
as described before, giving a Wnal concentration of
33 mg/ml [4]. Formulated DOX (Doxorubicin hydro-
chloride, 2 mg/ml) was obtained from Pharmachemie
B.V. (Haarlem, The Netherlands). Before injection,
the content of the vial was dissolved in a sterile 0.9%
NaCl solution to obtain a concentration of 1 mg/ml.
Animals
Twenty-four male BALB/c mice (20–25 g) obtained
from Harlan Nederland (Horst, The Netherlands)
were kept in a light- and temperature-controlled room
(21–22°C; humidity 60–65%). The animals were fed a
standard diet (Harlan Teklad) and allowed to eat and
drink tap water ad libitum. The animals were allowed
to adapt to the laboratory housing conditions for
2 weeks before starting the experiment.
Experimental design
The protocol was approved by the Ethics Committee
for animal experiments of the Vrije Universiteit
(Amsterdam, The Netherlands).
The mice received one of the following weekly dose-
schedules for 6 weeks:
Group I (n = 6) 0.5 ml 0.9% NaCl solution i.p.,
followed by 0.1 ml 0.9% NaCl
solution i.v.
Group II (n = 6) 0.5 ml 0.9% NaCl solution i.p.,
followed by 4 mg/kg DOX i.v.
Group III (n = 6) 500 mg/kg monoHER i.p., followed
by 4 mg/kg DOX i.v. after 60 min.
Group IV (n = 6) 500 mg/kg monoHER i.p., followed
by 4 mg/kg DOX i.v. after 60 min.
In addition the i.p. injection with
500 mg/kg monoHER was con-
tinued once every week during the
observation period of 26 weeks.
DOX was administered via the tail vein. During treat-
ment and the 26 weeks of observation thereafter, body
weight was determined once a week as a measure of
general toxicity. After this long period of observation
or earlier when necessitated by the bad condition of an
animal, the animals were sacriWced. The hearts were
excised and the central part of both ventricles was cut
into 5-mm-thick pieces of 2–3 mm, which were Wxed in
4% phosphate buVered formaldehyde solution.
Histological analyses
After Wxation in 4% phosphate buVered formalde-
hyde solution, the heart tissue was post Wxed in 1%123
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through a graded series of ethanol solutions of
70–95% and embedded in JB-4 Plus resin. Thereaf-
ter 0.5–3.0 m-thick sections were cut with a glass
knife. These semithin sections were examined by
light microscopy and the myocardial damage was
evaluated according to Billingham [1]. For this pur-
pose, the percentage of cardiac myocytes that had
been damaged was determined. Cardiac myocytes
with more than two vacuoles and/or loss of myoW-
brils were considered to be damaged. The scoring
area was measured using a commercially available
interactive video overlay based measuring system
(Q-Prodit, Leica, Cambridge, UK) [25]. For each
mouse the number of aberrant myocytes per mm2
was scored.
Results
EVect on behavior and condition of the mice
The mice of the saline group appeared lively through-
out the whole period of the study and no behavioral
changes were observed. Their weight increased during
these months.
After the Wrst 8 weeks of treatment, behavior of
the animals appeared normal in all treatment groups.
No signs of decreased activity and no signiWcant
diVerences in weight gain between the groups were
observed, indicating low general toxicity. Table 1
illustrates characteristics of the mice per experimen-
tal group during the whole study. During the observa-
tion period of 26 weeks, nine mice from the groups
treated with DOX were sacriWced. All of them had
shortness of breath, a decreased activity, loss of appe-
tite and Wnally as a consequence loss of weight of
more than 10%. Their fur looked bad and the animals
arched their back. These symptoms were indicated as
clinical signs of congestive heart failure (CHF). Three
mice were found dead in their cage during the obser-
vation period. Two of them already showed loss of
weight, but the third mouse died unexpectedly. The
remaining animals in group II and III survived with-
out problems (no signs of decreased activity or signiW-
cant diVerences in weight gain) until the end of the
study. Five out of six animals of the fourth group
treated with monoHER once every week during the
observation period ended up in a bad condition,
showing the earlier described features. Therefore, the
mice were sacriWced, or died before the end of the
study. Mouse V-21 was not in a bad condition, but
died unexpectedly.
Symptoms of CHF observed in sacriWced 
and dead animals
Nine mice from group II–IV were sacriWced before the
end of the study. Eight of them were evaluable. The
data of animal IV-19 got lost. All nine mice showed
loss of weight progressing rapidly during the last days
before their sacriWce. During autopsy, it was clear that
all animals were starved. The heart was enlarged in the
eight mice and some of them had also some pleural
Xuid, which is indicative of CHF. Of the three animals
found dead in their cage, one (IV-20) showed an
enlarged heart. No signs of cardiac failure or another
cause of death was found during autopsy in the other
two mice, but one of them (III-13) showed signs of
starvation.
Microscopic evaluation of the heart tissue 
of all animals
A number of animals died at diVerent times in the fol-
low-up period. Because DOX-induced cardiotoxicity is
progressing with time, a statistical comparison of myo-
cardial damage in the mice of the four experimental
groups was not feasible anymore. Nevertheless, the
percentage of damaged cardiac myocytes was evalu-
ated. Cardiac myocytes with more than two vacuoles
and/or loss of myoWbrils were considered damaged. An
overview of the aberrant cardiac myocytes/mm2 in the
animals of the experimental groups is also presented in
Table 1. Overall, heart tissue of animals treated with
saline had a low score. The diVerence between the
score of the saline-treated mice and the animals of the
other experimental groups was remarkable, whereas
between the three groups treated with DOX with or
without monoHER hardly any diVerence was
observed. Besides the (almost) absence of vacuolar
degeneration in the cardiac myocytes of the mice
treated with saline, their cardiac cells also showed a
higher concentration of myoWbrils in comparison to the
other experimental groups.
Discussion
Several studies showed that the long-term eVect of
DOX on cardiac tissue may progress in time to more
severe myocardial injury resulting in cardiomyopathy
or even CHF [11, 18]. Therefore, advances in long-
term survival achieved over the last two decades for
e.g.; acute leukaemia in childhood necessitate obtain-
ing favorable long-term eVects of DOX-containing
anticancer treatment [12]. Thus, it is desirable to123
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tion. MonoHER, a Xavonoid with proven cardiopro-
tecting properties [4, 23, 24], and at present in a clinical
phase  study, is expected to be such a compound.
The results of this study corroborate that monoHER
given 1 h before DOX is protecting in vivo against
DOX-induced cardiotoxicity within the Wrst 8 weeks of
treatment. Its cardioprotective eVect is present for a
longer period of time thereafter, but towards the end
of 26 weeks of observation, the cardioprotection by
monoHER is not present anymore and toxicity
becomes comparable to that in DOX-treated animals.
Continuation of weekly injections of monoHER (after
DOX administration was ended) during the observa-
tion period even seems to aggravate the development
of DOX-induced cardiotoxicity.
At the end of the study no diVerence in survival was
observed between the mice treated with DOX alone
and the animals treated with DOX-monoHER (group
III), while the mice treated with monoHER once
every week during the observation period even
showed a decreased survival rate in comparison to the
DOX-treated mice.
It is known however that Xavonoids which can act as
antioxidants, may display pro-oxidant action at higher
doses [3, 15, 21] and/or when administered for an
extended period of time [3]. One of the reasons for this
change may be that compounds such as Xavonoids and
carotenoids which act as eVective scavengers of reac-
tive oxygen species, may themselves become reactive
oxidation products [2, 3]. These secondary formed
toxic products may interact with lipids, proteins and
DNA giving rise to (pro-oxidant) cytotoxic as well as
genotoxic eVects.
Also, Boots et al. [2] showed that during its antioxi-
dant activity quercetin becomes oxidized. This oxi-
dized form is toxic since it reacts with for example the
thiol glutathione (GSH), which results in a decreased
amount of this cellular antioxidant.
Because of these properties, it may be that mono-
HER—being a structural analog of quercetin—was
administered at a too high dose in the animals receiv-
ing monoHER just before DOX (group III) and espe-
cially in the animals receiving monoHER also once
every week during the observation period (group V).
Therefore, it could be that the created overdose of the
antioxidant monoHER started to behave as a pro-
oxidant as shown for other Xavonoids before [7, 15, 19,
21]. Another possible explanation may be that mono-
HER becomes a reactive oxidation product and thus
Table 1 Characteristics of 
the mice per experimental 
group
Mouse 
(Group, #)
Time of 
death 
(weeks)a
SacriWced 
(S)/death (D)
Pleural 
Xuid 
(Y/U)
Enlarged 
heart 
(Y/U)
Weight 
Loss
Score/mm2

1 10
2 5.5
3 0.4
4 2.2
5 1.5
6 1.4
II
7 10 S Y Y Y 16.8
8 25.9
9 15.6
10 24.8
11 17 S Y Y 18.8
12 24 S U U Y N
III
13 17 D U U Y 5.3
14 21 S Y Y 5.8
15 14.5
16 18 S Y Y 23.6
17 19.8
18 11.7
V
19 10 S Y Y Y N
20 17 D Y Y 12.5
21 12 D N
22 13 S Y Y 16.7
23 17 S Y Y Y 16.1
24 18 S Y Y NE
Groups:  saline, II DOX 
alone, III DOX-monoHER, 
V DOX-monoHER + mono-
HER once every week
Y yes, U unknown, informa-
tion was lost, Score/mm2  
abnormal cardiac myocytes/
mm2  scored according to 
Billingham, N no material 
available, NE tissue not suit-
able for evaluation
a Weeks from the start of the 
observation period 123
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dants.
The physical problems in the mice treated with
monoHER every week (group V) developed earlier
and were more severe in comparison to the mice
treated with DOX-monoHER (group III). This seems
to underline the concentration-dependent pro-oxida-
tive properties of monoHER. The right balance
between the dose of monoHER and its anti- and pro-
oxidant properties has not been established yet. This
will play a key role in the further development of
monoHER as a cardioprotector.
During microscopic evaluation of the cardiac dam-
age we observed that the cardiac cells of mice treated
with saline showed a higher density of myoWbrils than
the surviving animals treated with DOX either with or
without monoHER. This observation—besides the
morphological changes in the cardiac tissues which are
included in the Billingham score (vacuolar degenera-
tion, loss of myoWbrils)—seems characteristic for long-
term DOX-induced cardiac damage, because it was not
seen in heart tissue of DOX-treated mice after a short
observation time.
The present study indicates that the dose of mono-
HER may be crucial in providing an optimal anti-oxi-
dant eVect without a pro-oxidant eVect, thus obtaining
the desired long-term cardioprotective eVect. These
aspects have to be elucidated in more detail.
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